CL2009001497A1 - Compounds derived from substituted 2- (3-pyridyl) -indole; pharmaceutical composition that includes them; and use in the treatment of disorders mediated by aldosterone synthetase, such as heart failure, arrhythmia, myocardial fibrosis, hypertrophic cardiomyopathy, among others. - Google Patents
Compounds derived from substituted 2- (3-pyridyl) -indole; pharmaceutical composition that includes them; and use in the treatment of disorders mediated by aldosterone synthetase, such as heart failure, arrhythmia, myocardial fibrosis, hypertrophic cardiomyopathy, among others.Info
- Publication number
- CL2009001497A1 CL2009001497A1 CL2009001497A CL2009001497A CL2009001497A1 CL 2009001497 A1 CL2009001497 A1 CL 2009001497A1 CL 2009001497 A CL2009001497 A CL 2009001497A CL 2009001497 A CL2009001497 A CL 2009001497A CL 2009001497 A1 CL2009001497 A1 CL 2009001497A1
- Authority
- CL
- Chile
- Prior art keywords
- arrhythmia
- indole
- treatment
- pharmaceutical composition
- heart failure
- Prior art date
Links
- KDWAJWXWMMNKHA-UHFFFAOYSA-N 2-pyridin-3-yl-1h-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CN=C1 KDWAJWXWMMNKHA-UHFFFAOYSA-N 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 206010003119 arrhythmia Diseases 0.000 title abstract 2
- 230000006793 arrhythmia Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Chemical class 0.000 title abstract 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 title 1
- 102000003960 Ligases Human genes 0.000 title 1
- 108090000364 Ligases Proteins 0.000 title 1
- 206010028594 Myocardial fibrosis Diseases 0.000 title 1
- 229960002478 aldosterone Drugs 0.000 title 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 abstract 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 abstract 1
- 206010052337 Diastolic dysfunction Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos derivados de piridin-3-il-indol sustituidos, composición farmacéutica, útil para el tratamiento de un trastorno mediado por la inhibición de la sintasa de aldosterona, como insuficiencia cardiaca, arritmia, disfunción diastólica, cardiomiopatía hipertrófica, muerte cardiaca repentina, fibrosis de miocardio, engrosamiento endotelial, entre otras.Compounds derived from substituted pyridin-3-yl-indole, pharmaceutical composition, useful for the treatment of a disorder mediated by the inhibition of aldosterone synthase, such as heart failure, arrhythmia, diastolic dysfunction, hypertrophic cardiomyopathy, sudden cardiac death, fibrosis of myocardium, endothelial thickening, among others.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2009001497A CL2009001497A1 (en) | 2009-06-26 | 2009-06-26 | Compounds derived from substituted 2- (3-pyridyl) -indole; pharmaceutical composition that includes them; and use in the treatment of disorders mediated by aldosterone synthetase, such as heart failure, arrhythmia, myocardial fibrosis, hypertrophic cardiomyopathy, among others. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2009001497A CL2009001497A1 (en) | 2009-06-26 | 2009-06-26 | Compounds derived from substituted 2- (3-pyridyl) -indole; pharmaceutical composition that includes them; and use in the treatment of disorders mediated by aldosterone synthetase, such as heart failure, arrhythmia, myocardial fibrosis, hypertrophic cardiomyopathy, among others. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001497A1 true CL2009001497A1 (en) | 2010-08-13 |
Family
ID=65681744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001497A CL2009001497A1 (en) | 2009-06-26 | 2009-06-26 | Compounds derived from substituted 2- (3-pyridyl) -indole; pharmaceutical composition that includes them; and use in the treatment of disorders mediated by aldosterone synthetase, such as heart failure, arrhythmia, myocardial fibrosis, hypertrophic cardiomyopathy, among others. |
Country Status (1)
| Country | Link |
|---|---|
| CL (1) | CL2009001497A1 (en) |
-
2009
- 2009-06-26 CL CL2009001497A patent/CL2009001497A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003532A (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF. | |
| ECSP19001018A (en) | BETA -3 ADRENERGIC RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO THE SAME | |
| EA201792536A1 (en) | TRIAZOLE AGONISTS APJ RECEPTOR | |
| CL2012002356A1 (en) | Heterocyclic acid compounds derived from bisyl-linked aryltriazolones, vasopressin receptor inhibitors v1a and v2; preparation procedure; pharmaceutical composition; and its use to treat and / or prevent acute and chronic heart failure, hyponatremia, among others. | |
| CL2012002037A1 (en) | Use of glucagon-glp-1 double agonist as an inotropic agent in the treatment of heart disease or cardiac dysfunction | |
| CL2013000104A1 (en) | Compounds derived from substituted nitrogen heterocyclics, ip receptor agonists; pharmaceutical composition; pharmaceutical combination; and use for the treatment of pulmonary arterial hypertension. | |
| PE20142301A1 (en) | URACILOS BICYCLICALLY REPLACED AND USE OF THE SAME | |
| NI201100144A (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING AMLOPIDINE AND LOSARTAN, AS WELL AS THE PROCESS TO PRODUCE THE SAME. | |
| CR20160032A (en) | PYRIMIDINODIONA COMPOUNDS AGAINST HEART STATES | |
| UY31796A (en) | CONDENSED CYCLOPENTANOCARBOXYL ACID DERIVATIVES SUBSTITUTED WITH ACILAMINE AND ITS USE AS PHARMACEUTICAL PRODUCTS. | |
| GT201400166A (en) | SYNTHETIC APELINE MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT | |
| CL2014000504A1 (en) | Compounds derived from substituted condensed pyrimidines; preparation procedure; pharmaceutical composition; and use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases. | |
| CR20130409A (en) | NEWS DERIVED FROM AZABENCIMIDAZOLCYCLIC USEFUL AS ANTI-DIABETIC AGENTS | |
| CL2007002689A1 (en) | COMPOUNDS DERIVED FROM PIPERIDIN-1-CARBOXAMIDA, INHIBITORS OF THE RENINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERTENSION, CARDIAC INSUFFICIENCY, CARDIAC FIBROSIS, AMONG OTHERS. | |
| CL2008001157A1 (en) | Compounds derived from quinoline-carboxamide, antagonists of p2y12; preparation procedure; pharmaceutical composition comprising said compound; composition of a combination of said compounds; and use of the compound in the treatment of cardiovascular disorders, thromboembolism, acute myocardial infarction. | |
| GT201600269A (en) | DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE | |
| UY36416A (en) | 1- [2- (AMINOMETIL) BENCIL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PIRROLO [3,2-D] PYRIMIDIN-4-WAVES AS INHIBITORS OF MYELOPEROXIDASE | |
| UY36118A (en) | COMPOUNDS AND COMPOSITIONS TO INDUCE CONDROGENESIS | |
| AR066168A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
| CL2007002097A1 (en) | Compounds derived from pyrrolidine or morpholine antagonists of urotensin ii; pharmaceutical composition comprising said compounds; and its use to treat congestive heart failure, ischemic heart failure, angina, myocardial ischemia, overactive bladder, asthma and / or copd, among others. | |
| TW201613932A (en) | Organic compounds | |
| CL2012002570A1 (en) | Compounds derived from 2- (3-heteroaryl-amino-1,2,3,4-tetrahydro-9h-carbazole) -acetic acid, pharmaceutical composition that comprises them, and their use as medicines, in the prophylaxis and / or treatment of pathologies mediated by modulation of prostaglandin d2 receptors, such as allergic or immune disorders. | |
| PE20141944A1 (en) | N- (6 - ((2R, 3S) -3,4-DIHYDROXIBUTAN-2-ILOXI) -2- (4-FLUOROBENZYLTIO) PYRIMIDIN-4-IL) -3-METHYLACETIDINE-1-SULPHONAMIDE AS CHEMOKIN RECEPTOR MODULATORS | |
| WO2016022536A3 (en) | Inhibitors of myh7b and uses thereof | |
| CL2008001205A1 (en) | Compounds derived from bicyclo [2.2.2] octene; pharmaceutical composition that contains them; and use in the treatment or prevention of stable chronic angina, hypertension, renal and cardiac ischemia, cardiac arrhythmias, cardiac hypertrophy and congestive heart failure. |